Impact of tumour size on axillary involvement and distant dissemination in breast cancer.
BACKGROUND
Tumour size and nodal involvement are the two main prognostic factors in breast cancer (BC). Their impact on the natural history of BC is not fully captured by analyses that ignore their quantitative nature.


METHODS
Data pertaining to 18 159 patients treated with primary surgery: 3661 at the Institut Gustave-Roussy (IGR, France) between 1954 and 1983, and 14 498 in the breast cancer registry in the Stockholm-Gotland Health Care region (SG, Sweden) between 1976 and 1999, were collected. The risks of distant metastases (DMs) and of nodal involvement were analysed according to tumour size with parametric models.


RESULTS
Using SG 1976-1990 as the reference group, relative risks (RRs) for DM were equal to 1.42 (95% CI: 1.29-1.56; P<10(-10)) in IGR and 0.61 (95% CI: 0.55-0.67; P<10(-10)) in SG 1991-1999. Differences in tumour size explained the increased risk in IGR (RR adjusted for tumour size 1.09; 95% CI: 0.99-1.20; P=0.07), but not the decreased risk in SG 1991-1999 (adjusted RR: 0.63; 95% CI: 0.57-0.69; P<10(-10)). The relationship between tumour size and DM risk changed significantly during the 1990s.


CONCLUSIONS
Early diagnosis is sufficient to explain differences in the prognosis before 1990. After 1990, the use of adjuvant systemic therapies is the main reason for the reduction in DM.
Koscielny
S
S
Department of Clinical and Translational Research, Institut Gustave-Roussy, Villejuif, France. koscielny@igr.fr
Arriagada
R
R
Adolfsson
J
J
Fornander
T
T
Bergh
J
J
D001365:Axilla; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
11602373
Cancer. 1989 Jan 1;63(1):181-7
2910416
Acta Oncol. 2009;48(1):59-66
18752084
Prev Med. 2005 Sep-Oct;41(3-4):728-33
16137757
Br J Cancer. 1984 Jun;49(6):709-15
6733019
J Clin Oncol. 2001 Feb 15;19(4):980-91
11181660
J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203
16106024
Lancet. 2002 Mar 16;359(9310):909-19
11918907
Br J Cancer. 1989 May;59(5):775-82
2736212
Acta Oncol. 2006;45(5):528-35
16864165
Lancet. 1998 May 16;351(9114):1451-67
9605801
Breast Cancer Res Treat. 1997 Sep;45(3):263-70
9386870
N Engl J Med. 2005 Oct 27;353(17):1784-92
16251534
Cancer. 2003 Nov 15;98(10):2133-43
14601082
Br J Cancer. 1985 Oct;52(4):515-24
4063132
Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1117-20
2254099
Cancer. 2003 Nov 15;98(10):2114-24
14601080
Lancet. 1998 Sep 19;352(9132):930-42
9752815